Geneva-based Light Chain Bioscience – Novimmune SA (LCB) has announced the launch of its first-in-human trial of NI-1801 in patients with solid advanced, metastatic, or recurrent solid malignancies expressing mesothelin (MSLN).
Geneva-based Light Chain Bioscience – Novimmune SA (LCB) has announced the launch of its first-in-human trial of NI-1801 in patients with solid advanced, metastatic, or recurrent solid malignancies expressing mesothelin (MSLN).